1. CNA-loaded PLGA nanoparticles improve humoral response againstS. aureus-mediated infections in a mouse model: subcutaneous vs. nasal administration strategy.
- Author
-
Genta I, Colonna C, Conti B, Caliceti P, Salmaso S, Speziale P, Pietrocola G, Chiesa E, Modena T, and Dorati R
- Subjects
- Adjuvants, Immunologic pharmacology, Adjuvants, Immunologic therapeutic use, Administration, Intranasal, Animals, Female, Immunity, Humoral, Mice, Mice, Inbred BALB C, Polylactic Acid-Polyglycolic Acid Copolymer, Staphylococcal Infections immunology, Staphylococcal Vaccines pharmacology, Staphylococcal Vaccines therapeutic use, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic pharmacology, Vaccines, Synthetic therapeutic use, Adjuvants, Immunologic administration & dosage, Drug Carriers chemistry, Lactic Acid chemistry, Nanoparticles chemistry, Polyglycolic Acid chemistry, Staphylococcal Infections prevention & control, Staphylococcal Vaccines administration & dosage, Staphylococcus aureus immunology
- Abstract
The aim of this work was the assessment of the "in vivo" immune response of a poly(lactide-co-glycolide)-based nanoparticulate adjuvant for a sub-unit vaccine, namely, a purified recombinant collagen-binding bacterial adhesion fragment (CNA19), against Staphylococcus aureus-mediated infections. "In vivo" immunogenicity studies were performed on mice: immunisation protocols encompassed subcutaneous and intranasal administration of CNA19 formulated as nanoparticles (NPs) and furthermore, CNA19-loaded NPs formulated in a set-up thermosetting chitosan-β-glycerolphosphate (chitosan-β-GP) solution for intranasal route in order to extend antigen exposure to nasal mucosa. CNA19 loaded NPs (mean size of about 195 nm, 9.04 ± 0.37μg/mg as CNA19 loading capacity) confirmed as suitable vaccine for subcutaneous administration with a more pronounced adjuvant effect (about 3-fold higher) with respect to aluminium, recognised as "reference" adjuvant. CNA19 loaded NPs formulated in an optimised thermogelling chitosan-β-GP solution showed promising results for eliciting an effective humoral response and a good chance as intranasal boosting dose.
- Published
- 2016
- Full Text
- View/download PDF